Business

Commercial Launch of Speedboat at UEG Week

Commercial Launch of Speedboat at UEG Week.

articleCreo Medical Group PlcOctober 22, 20193/company/creo-medical-group-plc/news/commercial-launch-of-speedboat-at-ueg-week
Commercial Launch of Speedboat at UEG Week

About this update from Creo Medical Group Plc

[{"type":"text","content":"\n \nRNS Number : 6700Q Creo Medical Group PLC 22 October 2019  \n\nCreo Medical Group plc\n(\"Creo\" or the \"Company\")\n \nCommercial Launch of Speedboat at UEG Week in Barcelona \nDemonstration of wider suite of gastro-intestinal products awaiting regulatory clearance\n \nCreo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces the full commercial launch of its Speedboat device, the first in a range of gastrointestinal ('GI') devices to be cleared for use with the CROMA Advanced Energy platform which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation. \n \nCreo will be exhibiting at the United European Gastroenterology ('UEG') Week Congress in Barcelona from 21-23, October 2019 show-casing the CROMA Platform, powered by its unique full spectrum adaptive technology along with the GI suite of products for the dissection, resection, haemostasis and ablation of soft tissue. These products enable a wide variety of procedures, all of which are targeting treatment in the endoscopy room instead of the operating theatre wherever possible. This will be the first time the suite of products will have been fully demonstrated to the market as plans are put in place for first human cases.\n \nHaemostasis device (HS1)* - is the ONLY non-stick haemostasis device in any sphere of therapy which builds on the excellent results seen clinically with the Speedboat device. \n \nResection device (RG1)* - is the ONLY bipolar RF scissors device in any sphere of therapy powered by the unique full spectrum adaptive technology in the CROMA platform. With capability to simultaneously utilise RF and Microwave energy this device truly brings laparoscopic surgical capability into the world of flexible endoscopic surgery.\n \nNarrow Probe ablation needle (NP1)* - is the SMALLEST microwave ablation device in any sphere of therapy, providing precise and accurate delivery of microwave energy for ablation of soft tissue in various tissue types, ideal for the management of various GI disease states\n \n*internal nomenclature\n \nThe commercial launch of the CROMA platform and Speedboat, along with the unveiling of a suite of devices at UEG Week is...

More updates from Creo Medical Group Plc